VR Logo

Lexaria Bioscience Corp. (LEXX) download report


Healthcare | Biotechnology & Pharma Research

Lexaria Bioscience Corp. (LEXX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery.

IPO Date: 10-Oct-2006

Chairman & CEO: Mr. Christopher A. Bunka

Pres & Director: Mr. John M. Docherty M.Sc.

Listing: NASDAQ: LEXX

Country: Canada

Headquarters: Kelowna, BC

Website: https://www.lexariabioscience.com

Key Facts

Market cap: $16.42 Mln

Revenue (TTM): $0.28 Mln

Earnings (TTM): $-7.15 Mln

Cash: $8.91 Mln

Total Debt: $0.00 Mln

Insider's Holding: 17.81%

Liquidity: Low

52 Week range: $1.86 - 12.50

Shares outstanding: 5,951,000

10 Years Aggregate:

  • CFO: $-15.43 Mln
  • EBITDA: $-18.81 Mln
  • Net Profit: $-24.11 Mln

Stock Performance

Time Period Lexaria Bioscience (LEXX) S&P BSE Sensex S&P Small-Cap 600
YTD-31.51-9.18-18.78
1 month33.98-4.78-8.00
3 months-16.36-9.66-13.65
1 Year-60.570.81-17.19
3 Years-52.6910.336.10
5 Years-21.1911.345.87
10 Years-5.3311.749.84
As on 01-Jul-2022
Year Lexaria Bioscience (LEXX) S&P Small-Cap 600 S&P BSE Sensex
2021-46.1225.2721.99
2020-34.829.5715.75
2019-58.8720.8614.38
2018-44.79-9.705.87
2017445.1611.7327.91
201693.7524.741.95
201590.89-3.36-5.03